Sage Therapeutics (SAGE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SAGE Stock Forecast

Sage Therapeutics stock forecast is as follows: an average price target of $38.89 (represents a 692.06% upside from SAGE’s last price of $4.91) and a rating consensus of 'Hold', based on 12 wall street analysts offering a 1-year stock forecast.

SAGE Price Target

The average price target for Sage Therapeutics (SAGE) is $38.89 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $9.00. This represents a potential 692.06% upside from SAGE's last price of $4.91.

SAGE Analyst Ratings

Hold

According to 12 Wall Street analysts, Sage Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for SAGE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (25.00%), 8 'Hold' (66.67%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Sage Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 30, 2024	Yasmeen Rahimi	Piper Sandler	$26.00	$7.90	229.11%	429.53%
Oct 30, 2024	George Farmer	Scotiabank	$14.00	$8.48	65.09%	185.13%
Oct 30, 2024	Vamil Divan	Mizuho Securities	$10.00	$7.86	27.31%	103.67%
Oct 30, 2024	Douglas Tsao	H.C. Wainwright	$14.00	$8.48	65.09%	185.13%
Aug 14, 2024	Joon Lee	Truist Financial	$13.00	$7.95	63.52%	164.77%
Aug 06, 2024	Sumant Kulkarni	Canaccord Genuity	$9.00	$8.88	1.35%	83.30%
May 28, 2024	Joel Beatty	Robert W. Baird	$15.00	$11.93	25.73%	205.50%
Apr 25, 2024	Joon Lee	Truist Financial	$18.00	$13.58	32.55%	266.60%
Apr 18, 2024	George Farmer	Scotiabank	$19.00	$12.57	51.15%	286.97%
Apr 17, 2024	Jay Olson	Oppenheimer	$17.00	$12.57	35.24%	246.23%

Row per page

Go to

The latest Sage Therapeutics stock forecast, released on Oct 30, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $26.00, which represents a 229.11% increase from the stock price at the time of the forecast ($7.90), and a 429.53% increase from SAGE last price ($4.91).

Sage Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	4	4	14
Avg Price Target	$16.00	$16.00	$17.93
Last Closing Price	$4.91	$4.91	$4.91
Upside/Downside	225.87%	225.87%	265.17%

In the current month, the average price target of Sage Therapeutics stock is $16.00, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 225.87% increase as opposed to Sage Therapeutics's last price of $4.91. This month's average price target is down 0.00% compared to last quarter, and down -10.76% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 30, 2024	Scotiabank	Outperform	Outperform	Hold
Oct 30, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Oct 30, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Oct 04, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Oct 04, 2024	RBC Capital	Underperform	Underperform	Hold
Oct 04, 2024	RBC Capital	Underperform	Sector Perform	Downgrade
Jul 30, 2024	J.P. Morgan	Underperform	Underperform	Hold
Jul 30, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Jul 30, 2024	Cowen & Co.	Buy	Hold	Downgrade

Row per page

Go to

Sage Therapeutics's last stock rating was published by Piper Sandler on Oct 30, 2024. The company gave SAGE a "Overweight" rating, the same as its previous rate.

Sage Therapeutics Financial Forecast

Sage Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.72M	$2.47M	$3.29M	$2.87M	$1.74M	$1.50M	$1.58M	$1.64M	$1.44M	$1.64M	$1.58M	$1.11B	$1.64M	$1.09M	$2.29M	$1.96M	$3.57M
Avg Forecast	$72.70M	$44.60M	$37.16M	$31.50M	$22.74M	$20.02M	$17.99M	$15.99M	$14.11M	$10.80M	$8.85M	$5.26M	$61.03M	$4.63M	$2.94M	$2.37M	$2.00M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
High Forecast	$105.16M	$64.51M	$53.76M	$45.56M	$32.90M	$28.95M	$26.02M	$26.01M	$17.28M	$11.03M	$8.85M	$5.26M	$130.59M	$32.08M	$4.25M	$3.43M	$2.90M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
Low Forecast	$44.72M	$27.43M	$22.86M	$19.37M	$13.99M	$12.31M	$11.06M	$8.08M	$10.40M	$10.57M	$8.85M	$5.26M	$2.61M	$1.00M	$1.81M	$1.46M	$1.23M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
# Analysts	3	3	4	5	4	5	2	7	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.84%	1.39%	1.43%	1.06%	0.85%	0.49%	0.92%	0.74%	0.82%	0.78%	568.34%	0.89%	1.24%	0.82%	0.54%	1.29%

Sage Therapeutics's average Quarter revenue forecast for Dec 23 based on 12 analysts is $61.03M, with a low forecast of $2.61M, and a high forecast of $130.59M. SAGE's average Quarter revenue forecast represents a 2147.22% increase compared to the company's last Quarter revenue of $2.72M (Sep 23).

Sage Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-144.32M	$-170.46M	$-155.47M	$-153.90M	$-141.20M	$-128.13M	$-122.92M	$-124.38M	$-129.80M	$-106.35M	$-93.18M	$975.54M	$-105.08M	$-135.69M	$-126.07M	$-167.99M	$-179.26M
Avg Forecast	$-49.98M	$-30.66M	$-25.55M	$-21.65M	$-15.64M	$-13.76M	$-12.37M	$-11.00M	$-9.70M	$-7.42M	$-6.09M	$-122.23M	$-41.96M	$-3.18M	$-2.02M	$-111.11M	$-139.97M	$-1.12M	$-1.20M	$-118.84M	$-1.21M	$-1.34M	$-1.36M	$-106.35M	$-1.33M	$-1.26M	$-599.14K	$-154.18M	$-2.50M	$-1.89M
High Forecast	$-30.75M	$-18.86M	$-15.72M	$-13.32M	$-9.62M	$-8.47M	$-7.61M	$-5.56M	$-7.15M	$-7.27M	$-6.09M	$-97.78M	$-1.80M	$-689.33K	$-1.24M	$-88.89M	$-111.98M	$-1.12M	$-1.20M	$-95.07M	$-1.21M	$-1.34M	$-1.36M	$-85.08M	$-1.33M	$-1.26M	$-599.14K	$-123.34M	$-2.50M	$-1.89M
Low Forecast	$-72.30M	$-44.35M	$-36.96M	$-31.32M	$-22.62M	$-19.91M	$-17.89M	$-17.88M	$-11.88M	$-7.58M	$-6.09M	$-146.67M	$-89.78M	$-22.06M	$-2.92M	$-133.34M	$-167.96M	$-1.12M	$-1.20M	$-142.61M	$-1.21M	$-1.34M	$-1.36M	$-127.63M	$-1.33M	$-1.26M	$-599.14K	$-185.01M	$-2.50M	$-1.89M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	45.32%	84.38%	1.40%	1.10%	125.70%	106.38%	1.03%	102.38%	97.06%	78.04%	0.88%	-731.84%	83.54%	226.47%	0.82%	67.25%	94.65%

4 analysts predict SAGE's average Quarter EBITDA for Mar 21 to be $-106.35M, with a high of $-85.08M and a low of $-127.63M. This is -110.90% lower than Sage Therapeutics's previous annual EBITDA (Dec 20) of $975.54M.

Sage Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-201.63M	$-160.32M	$-138.19M	$-133.31M	$-129.04M	$-122.01M	$-119.74M	$-124.71M	$-130.17M	$-107.25M	$-95.76M	$974.89M	$-105.73M	$-136.35M	$-126.74M	$-168.65M	$-179.96M
Avg Forecast	$-36.06M	$-58.67M	$-61.73M	$-63.56M	$-67.66M	$-70.28M	$-74.10M	$-78.76M	$-92.79M	$-94.27M	$-100.30M	$-123.69M	$-78.02M	$-163.98M	$-156.09M	$-112.44M	$-140.34M	$-134.17M	$-129.21M	$-120.26M	$-129.11M	$-111.41M	$-101.11M	$-109.30M	$-126.16M	$-139.37M	$-154.88M	$-154.99M	$-216.04M	$-206.19M
High Forecast	$-18.02M	$-29.32M	$-30.84M	$-31.76M	$-33.81M	$-35.12M	$-37.03M	$-65.84M	$-61.65M	$-47.10M	$-50.12M	$-98.95M	$35.04M	$-89.50M	$-77.99M	$-89.95M	$-112.28M	$-134.17M	$-129.21M	$-96.21M	$-129.11M	$-111.41M	$-101.11M	$-87.44M	$-126.16M	$-139.37M	$-154.88M	$-124.00M	$-216.04M	$-206.19M
Low Forecast	$-56.99M	$-92.72M	$-97.55M	$-100.45M	$-106.94M	$-111.08M	$-117.11M	$-94.76M	$-126.42M	$-148.98M	$-158.51M	$-148.42M	$-169.27M	$-204.23M	$-246.68M	$-134.93M	$-168.41M	$-134.17M	$-129.21M	$-144.31M	$-129.11M	$-111.41M	$-101.11M	$-131.16M	$-126.16M	$-139.37M	$-154.88M	$-185.99M	$-216.04M	$-206.19M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.23%	1.03%	1.23%	0.95%	0.96%	0.94%	1.00%	0.97%	1.17%	1.06%	0.88%	-7.73%	0.76%	0.88%	0.82%	0.78%	0.87%

Sage Therapeutics's average Quarter net income forecast for Mar 21 is $-109.30M, with a range of $-131.16M to $-87.44M. SAGE's average Quarter net income forecast represents a -111.21% decrease compared to the company's last Quarter net income of $974.89M (Dec 20).

Sage Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$78.14M	$75.56M	$65.71M	$67.33M	$61.48M	$52.41M	$46.48M	$51.60M	$48.71M	$43.35M	$39.85M	$53.50M	$35.10M	$38.22M	$70.13M	$85.13M	$88.50M
Avg Forecast	$1.63B	$1.00B	$835.57M	$708.11M	$511.31M	$450.02M	$404.37M	$359.57M	$317.26M	$242.79M	$199.00M	$118.28M	$1.37B	$104.14M	$66.06M	$53.34M	$45.01M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
High Forecast	$2.36B	$1.45B	$1.21B	$1.02B	$739.58M	$650.94M	$584.90M	$584.72M	$388.39M	$247.90M	$199.01M	$118.28M	$2.94B	$721.33M	$95.55M	$77.16M	$65.10M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
Low Forecast	$1.01B	$616.78M	$513.98M	$435.58M	$314.52M	$276.82M	$248.74M	$181.66M	$233.71M	$237.67M	$199.00M	$118.27M	$58.72M	$22.54M	$40.64M	$32.81M	$27.69M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.14%	1.23%	1.50%	1.66%	1.32%	0.64%	1.29%	1.11%	0.97%	0.87%	1.22%	0.85%	1.94%	1.12%	1.04%	1.42%

Sage Therapeutics's average Quarter SG&A projection for Dec 23 is $1.37B, based on 12 Wall Street analysts, with a range of $58.72M to $2.94B. The forecast indicates a 1656.05% rise compared to SAGE last annual SG&A of $78.14M (Sep 23).

Sage Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	4	5	4	5	2	7	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.37	$-2.68	$-2.32	$-2.24	$-2.17	$-2.06	$-2.03	$-2.12	$-2.21	$-1.83	$-1.64	$18.71	$-2.03	$-2.63	$-2.44	$-3.25	$-3.48
Avg Forecast	$-0.59	$-0.96	$-1.01	$-1.04	$-1.11	$-1.15	$-1.21	$-1.29	$-1.52	$-1.54	$-1.64	$-1.65	$-1.28	$-2.68	$-2.55	$-2.51	$-2.38	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
High Forecast	$-0.29	$-0.48	$-0.50	$-0.52	$-0.55	$-0.57	$-0.61	$-1.08	$-1.01	$-0.77	$-0.82	$-0.82	$0.57	$-1.46	$-1.28	$-1.25	$-1.19	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
Low Forecast	$-0.93	$-1.52	$-1.60	$-1.64	$-1.75	$-1.82	$-1.92	$-1.55	$-2.07	$-2.44	$-2.59	$-2.61	$-2.77	$-3.34	$-4.04	$-3.96	$-3.76	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26%	1.05%	0.93%	0.94%	0.98%	0.97%	0.99%	0.99%	1.20%	1.10%	0.88%	-8.98%	0.88%	1.03%	0.81%	0.91%	1.02%

According to 4 Wall Street analysts, Sage Therapeutics's projected average Quarter EPS for Mar 21 is $-1.87, with a low estimate of $-1.87 and a high estimate of $-1.87. This represents a -110.01% decrease compared to SAGE previous annual EPS of $18.71 (Dec 20).

Sage Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.78	$33.86	1802.25%	Buy
SAGE	Sage Therapeutics	$4.91	$38.89	692.06%	Hold
BDTX	Black Diamond Therapeutics	$2.55	$14.75	478.43%	Buy
RLAY	Relay Therapeutics	$4.80	$19.40	304.17%	Buy
ARVN	Arvinas	$21.64	$71.00	228.10%	Buy
PLRX	Pliant Therapeutics	$12.79	$39.71	210.48%	Buy
DAWN	Day One Biopharmaceuticals	$13.52	$38.80	186.98%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
APLS	Apellis Pharmaceuticals	$28.99	$74.50	156.99%	Buy
TERN	Terns Pharmaceuticals	$5.91	$14.25	141.12%	Buy
IMCR	Immunocore	$32.56	$70.75	117.29%	Buy
DMAC	DiaMedica Therapeutics	$4.04	$8.33	106.19%	Buy
AKRO	Akero Therapeutics	$31.03	$46.00	48.24%	Buy
AMLX	Amylyx Pharmaceuticals	$5.22	$6.67	27.78%	Buy
NUVL	Nuvalent	$91.06	$111.57	22.52%	Buy
INCY	Incyte	$70.56	$84.56	19.84%	Buy
BPMC	Blueprint Medicines	$94.60	$109.71	15.97%	Buy
ALNY	Alnylam Pharmaceuticals	$234.27	$254.21	8.51%	Buy
KRYS	Krystal Biotech	$177.85	$191.00	7.39%	Buy
MDGL	Madrigal Pharmaceuticals	$314.17	$315.75	0.50%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

SAGE Forecast FAQ

Is Sage Therapeutics a good buy?

No, according to 12 Wall Street analysts, Sage Therapeutics (SAGE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 25.00% of SAGE's total ratings.

What is SAGE's price target?

Sage Therapeutics (SAGE) average price target is $38.89 with a range of $9 to $105, implying a 692.06% from its last price of $4.91. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sage Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SAGE stock, the company can go up by 692.06% (from the last price of $4.91 to the average price target of $38.89), up by 2038.49% based on the highest stock price target, and up by 83.30% based on the lowest stock price target.

Can Sage Therapeutics stock reach $7?

SAGE's average twelve months analyst stock price target of $38.89 supports the claim that Sage Therapeutics can reach $7 in the near future.

What is Sage Therapeutics's current price target trend?

4 Wall Street analysts forecast a $16 price target for Sage Therapeutics (SAGE) this month, up 225.87% from its last price of $4.91. Compared to the last 3 and 12 months, the average price target increased by 225.87% and increased by 265.17%, respectively.

What are Sage Therapeutics's analysts' financial forecasts?

Sage Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $76.74M (high $113.87M, low $45.45M), average EBITDA is $-52.759M (high $-31.245M, low $-78.29M), average net income is $-291M (high $-172M, low $-430M), average SG&A $1.73B (high $2.56B, low $1.02B), and average EPS is $-4.758 (high $-2.811, low $-7.034). SAGE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $185.96M (high $268.98M, low $114.39M), average EBITDA is $-128M (high $-78.645M, low $-185M), average net income is $-220M (high $-110M, low $-348M), average SG&A $4.18B (high $6.05B, low $2.57B), and average EPS is $-3.6 (high $-1.799, low $-5.689).

Did the SAGE's actual financial results beat the analysts' financial forecasts?

Based on Sage Therapeutics's last annual report (Dec 2023), the company's revenue was $86.46M, beating the average analysts forecast of $70.98M by 21.81%. Apple's EBITDA was $-580M, beating the average prediction of $-158M by 266.34%. The company's net income was $-541M, beating the average estimation of $-511M by 6.06%. Apple's SG&A was $274.52M, missing the average forecast of $1.6B by -82.80%. Lastly, the company's EPS was $-0.009, missing the average prediction of $-9.02 by -99.90%. In terms of the last quarterly report (Sep 2023), Sage Therapeutics's revenue was $2.72M, missing the average analysts' forecast of $4.63M by -41.37%. The company's EBITDA was $-144M, beating the average prediction of $-3.185M by 4431.69%. Sage Therapeutics's net income was $-202M, beating the average estimation of $-164M by 22.96%. The company's SG&A was $78.14M, missing the average forecast of $104.14M by -24.97%. Lastly, the company's EPS was $-3.37, beating the average prediction of $-2.683 by 25.60%